Latest Diagnostic Software News

Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Rewardle Holdings Limited reported a 2.8% revenue increase to $9.68 million for FY24 but swung to a $3.44 million net loss, driven by rising expenses and associate losses. The company expanded its footprint with acquisitions in grocery delivery and fintech, while deepening its stake in AI-powered health tech partner CloudHolter.

Rewardle Holdings reported a strong March quarter with positive operational cash flow of $1.36 million, driven by its strategic partnership with MedTech firm CloudHolter, while progressing towards ASX relisting.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Rewardle Holdings reports a strong December quarter with positive cash flow and a significant valuation uplift in its CloudHolter partnership, underpinning its multi-pronged growth strategy.